CSL Limited
HomeAll Profiles
July 1, 2020
Updated on:

CSL Limited

Revenue:
USD 8,538.6 million (2019)
Profit:
USD 1,918.7 million (2019)
Employees:
25,000 (2019)
Headquarters:
Parkville, Victoria, Australia
Founded:
1916
Current CEO:
Paul Perreault (July 2013-)
Parent:
This is the ultimate parent

Description

CSL Limited is a biotechnology company that engages in the research, development, manufacture, and marketing of products to treat and prevent medical conditions. The company was founded in 1916 as Commonwealth Serum Laboratories to service the health needs of a nation isolated by war. CSL Limited operates in over 35 countries and is headquartered in Parkville, Victoria, Australia.

On 31 July 2015, following the acquisition of the Novartis influenza vaccines business, CSL Limited established Seqirus. Seqirus manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Seqirus operates production facilities in the United States, the United Kingdom and Australia.

For the financial year end 30 June 2019, CSL Limited spent USD 832 million on research and development (R&D) investment, and employed 1,700 people in R&D roles.

CSL Limited is listed on the Australian Securities Exchange (ASX) under the code CSL.

In United States Dollars (USD)
In United States Dollars (USD)
In United States Dollars (USD)
No items found.

Operating Segments:

CSL Behring - CSL Behring manufactures, markets, and develops plasma therapies, conducts early stage research on plasma and non-plasma therapies (excluding influenza), receives licence and royalty income from the commercialisation of intellectual property and undertakes the administrative and corporate function required to support the company and subsidiaries. For the financial year end 30 June 2019, CSL Behring accounted for 86.00% (USD 7,342.9 million) of total operating income.

Seqirus - Seqirus manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. For the financial year end 30 June 2019, Seqirus accounted for 14.00% (USD 1,195.7 million) of total operating income.

Mergers and Acquisitions:

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Signup to a free account to access M&A data!

Signup for FREE to access all mergers and acquisitions data!
BigDiscover is the only platform to offer M&A data completely for free!

Click Here to Signup for FREE
Copyright © 2020 BigDiscover. All rights reserved.